Group plc (AIM: CREO), a medical device company specializing in minimally invasive surgical endoscopy, has completed the sale of a 51% interest in its European subsidiary, Creo Medical S.L.U., to ...

The Speedboat Submucosal Dissection (SSD) device, developed by Chepstow-based and Alternative Investment Market listed Creo Medical, offers a minimally invasive alternative to traditional surgery, ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A health board has become the first in Wales to implement a technology to treat Colon cancer, developed by Welsh med-tech company Creo Medical. Aneurin Bevan University Health Board (ABUHB) will pilot ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Creo Medical Group PLC has a twelve month low of GBX 12 ($0.15) and a twelve month high of GBX 43 ($0.53). The company has a market cap of £66.93 million, a P/E ratio of -308.33 and a beta of 0.86.

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company’s ...

(Alliance News) - Creo Medical Group PLC on Wednesday said it has completed the sale of a 51% stake in its European subsidiary for net proceeds of around EUR30 million.

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC ...